Bayer Tops Emerging Markets Index For Q311

BMI Core View: Emerging markets will drive industry growth. The importance of emerging markets to large multinational drugmakers cannot be overstated and BMI's Pharmaceutical Expenditure Model shows that five-year compound annual growth rates (CAGRs) in traditional markets, such as the US, Western Europe and Japan, are either in the low single figures or negative in some cases. The US dollar five-year CAGRs for the main emerging markets, Brazil, Russia, India and China, are expected to post double-digit

To read the full article, please choose one of the following options: